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A range of dietary products has been used in Asia as a common remedy to prevent or cure various diseases. The 
extracts from medicinal mushrooms (stem, butt and root rot) are utilized for the treatment of multiple diseases. As we 
know that mushroom is an abundant source of various minerals such as vitamins, fiber and different type of amino acids 
along with low in fat, cholesterol and calories. Carbohydrates and protein of proteoglycans are in 11.5:1 ratio. In 
addition, major 03 monosaccharides were present in carbohydrates i.e., D-glucose, D-galactose and D-mannose in the 
molar concentration of 3:1:1. The edible mushroom fungus, Ganoderma lucidum reportedly introduces many compounds 
as well as triterpenoids, polysaccharides, proteoglycans or glycopeptides, sterols, steroids and fatty acids with a role in 
prevention or cure for various diseases like that immunomodulation, anti-atherosclerotic, anti-inflammatory, analgesic, 
chemo-preventive, antitumor, antimicrobial, anti-HIV, anti-diabetic, anti-fibrotic, hepatoprotective, anti-androgenic, anti-
herpetic, anti-angiogenic, antioxidative, free radical-scavenging, anti-aging, hypoglycemic along with estrogenic activity 
properties. This review summarizes the cultivation and biologically active compounds of G. lucidum with various 
therapeutic applications. 
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G. lucidum is a basidiomycete belongs to the family 
of Polyporaceae. It is also known as ‘Lingzhi’ in 
China, ‘Reishi’ in Japan,‘Yeong Ji’  or ‘Yung Gee’or 
‘Seon-cho’ in Korea, ‘Linh chi’ in Vietnam and 
‘Lingzhi’ or ‘ling chih’ in English1,2. It was commonly 
used as a traditional medicine in the orient for more 
than 2000 years3. The first mention of this mushroom 
dates from the period of the first emperor of China, 
Shih-Huang (221–227 BC) of the Ch’in Dynasty4. 
Members of the Ganodermataceae family are defined 
by distinctive double-walled basidiospores. The shape 
and size of basidiospores and the pileus surfaces are 
significant features that differentiate family members. 
The macro and micro-morphological characters are 
widely variable with more than 250 species being 
described5. Therefore, it is the most challenging genus 
among the polypores to be classified6,7. The 
variability of Ganoderma morphological features 
resulted in many taxonomists to investigate chemical 
and molecular techniques for discriminating between 
Ganoderma species. 
Mushrooms are known to be rich in high-quality 
protein, contain a high proportion of unsaturated fatty 
acid and have a nucleic acid content low sufficient to 
allow daily use as a vegetable. These fungi are used 
for medicinal purpose. Several studies have shown 
that Ganoderma parts have multiple medicinal 
impacts including inhibition of Ras-dependent cell 
transformation, anti-fibrotic activity, immune 
modulating activity and free-radical scavenging 
activities8-11. 
 
ATTRIBUTES OF G. LUCIDUM GENOME  
The whole-genome sequence assembly of G. 
lucidum consists of 82 scaffolds, which contains 13 
chromosomes with a complete length of genome 
assembly was 43.3 Mb. A total of 16,113 genes were 
predicted with an average length of sequence 1556bp. 
Percentage (%) of GC content is 55.9 and protein-
coding gene GC content is 59.3. An average amount 
of exons per gene 4.7, while the average length of 
exons, introns, intergenic regions and coding 
sequence is 268bp, 87bp, 1206bp and 1188 
respectively12,13. —————— *Corresponding author 
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HISTORY 
Names for the lingzhi mushroom have a two 
thousand year history. The Chinese term lingzhi was 
first used record maintains during the Eastern Han 
dynasty (25–220 CE). Karsten proposed the name of 
the genus Ganoderma14. Lingzhi is the Chinese name 
for G. lucidum. It means the Spiritual Herb that 
Energizes the Chi or Life force. The first Chinese 
Emperor Chin Shi Huang Ti even called it the Herb of 
Deathlessness. In the Emperors of the ancient period, 
the mushroom was considered so important that they 
have given it names like The Elixir of Immortality, 
Herb of Spiritual Potency and Soup of the Emperor 
with a Thousand Mistresses. The mushroom did not 
exist in China as medicine alone but also as a symbol 
of prosperity, immortality and energy as can be 
judged from the inscription carved on various parts of 
the royal palaces. English botanist William Curtis 
coined the term Boletus lucidus, for the G. lucidum in 
1781. The term lingzhi botanical names have comes 
from Greek and Latin roots15. 
 
HABITAT & HABIT 
It was reported to grow in the Northern Eastern 
Hemlock forests. Bracket fungus species have a 
global distribution in each of these tropical and 
temperate geographical areas as well as discovered in 
Amazon. It is native to Asian region16,17. Lingzhi 
arises on deciduous trees at base and stumps, 
particularly on maple18. Nowadays, Lingzhi is 
effectively grown indoor and outdoor on logs or 
woodchip beds under sterile conditions. It is a 
heterotrophic fungus. However, it often is also 
saprophytic and feeds on the organic tissue of a dead 
organism.  In the case of G. lucidum, the dead tissue 
is usually from a few trees, which can diverge with 
the locality. However, it should be noted that in a few 
cases it is truly a parasite that attacks living trees. A 
parasite is a symbiotic relationship where one 
organism benefits and other organism have a loss. The 
hyphae enter into the plant at an injured or weakened 
area of the plant19. 
TYPES: G. lucidum (Reishi) has a different color 
such as Red, White, Black, Yellow, Purple and 
Blue/green. It was classified by color into 06 types 
(Table 1). 
 
CULTURE AND CULTIVATION 
CULTURE MEDIA: G. lucidum species were 
cultured on PDA media. The media were sterilized by 
autoclaving at 121-6°C (15 lbs psi) for 20 min.PDA 
was prepared accordingly20 and included 200 gm Lit-1 
potato extract, 20 g Lit-1 dextrose and 20 gm Lit-1 
Agar. 
Preparation of Mushroom culture from 
Mushroom Tissues: Young and vigorously growing 
mycelial tissue are used for culturing of mushrooms. 
Young tissues can be obtained after removal of the 
surface layers of tissues from the fruiting body. 
Firstly, fresh fruiting body of the mushroom is 
selected and washes with running tap water to remove 
dust/soil particles adhering to its surface. The outer 
layer of the fruiting body is removed by razor and 
with fresh tissue from the inner position of the fruiting 
body is taken out and excised into small pieces (2-4 
mm), Surface sterilize with 0.1% mercuric chloride 
for few seconds. The cut pieces are then washed in 
sterilized distilled water three times aseptically and 
then finally inoculated into media slants in culture 
tubes or media in Petri plates. Cultures are incubated 
at 26˚C for the attainment of growth of the mushroom 
mycelium21. 
Spawn Preparation: The spawn was prepared on 
wheat grains in half-liter capacity glass bottles. For 
this, the grains were cleaned to remove the dust 
particle. After that, the grains were dipped into fresh 
water and washed. Then boiled (wheat grain and 
water 1:25 w/v) in water for 20-25 min, taking care 
not to break the grains during cooking. The boiled 
grained were spread over wired net for the removal of 
excess water and put for overnight for cooling at 20-
250C. The cooled grain mixed with 1.2% of gypsum 
(CaSO4) for prevention of stickiness between the 
wheat grain and 0.3% calcium carbonate (CaCO3) 
maintained the pH 5.5-7.5. The grains were packed 
upto 2/3 of their ability in smooth glass bottles. The 
bottles were logged in non-absorbent cotton as well as 
coated with aluminum foil. Packed bottles were 
sterilized for 90 min at 1210C and 15psi; sterilized 
bottles were removed from autoclave while still hot 
and shaken to prevent clumping of grains, followed 
by bottles were inoculated with bits of the 
aggressively growing culture of the different strains. 
Inoculated bottles were inoculated at 30±1˚C and 
shaking is done after 7 days21. The spawn was ready 
when the whole grain was surrounded with thin 
mycelial growth (Fig. 1). This spawn is known as 
mother or master spawn. 
Substrate Preparation: Wheat straw used as a 
substrate and soaked in water with treated using 
Babustin 7.0 g + formalin 100 mL/100 L. for 18 h. The 
mouth of the tank was wrapped with polythene sheet to 
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avoid formalin evaporation. Moreover, straw was 
removed from the tank and retained for 2.3 h to drain 
out the water and spread for two hours on smooth 
cemented ground pre-treated with 2% formalin21. 
CULTIVATION: To cultivate the macro fungi the 
agricultural waste/straw of wheat was dipped in clean 
water for about 12 to 18 h and excess water was 
removed (waste material should contain the moisture to 
about 50 to 55%). The required material (waste 
material of wheat and rice @ 10%, magnesium 
sulphate @ 1%, calcium sulphate 0.5%) was taken in 
polypropylene bag of capacity 2 kg autoclaved at  
 
Table 1 — G. lucidum (Reishi) was classified by color into six types 
S.No. Colour Japan name Taste Medicinal Uses Visibility Reference 
1. Red Akashiba Bitter Aids internal organs  
and improves memory 
 
97 
2. White Shiroshiba Hot Protects kidney 
 
97 
3. Black Kuroshiba Salty Improves lung function 
 
97 
4. Yellow Kishiba Sweet Strengthen spleen  
function 
 
97 
5. Purple Murosakishiba Sweet Enhances the function  
of eyes joints, helps 
complexion. 
 
97 
6. Blue/ Green Aoshiba Sour Improves eye sight  
and liver function. 
 
97 
Source of image: www.image.google.com 
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22 psi for 1.5 h. The seed (mother spawn) which is 5% 
of the straw material was shown on the above and 
keeping it at 25 to 280C. After 30 to 40 days network of 
fungi is done. After developing the network of fungi 
remove these bags and sprinkling with water 2 to 3 
times in a day and maintaining the moisture about 85 to 
90%. After 14 to 15 days harvesting of fruiting body 
and production is near about 150 to 220 g/kg of dry 
straw weight21(Fig.1). 
COMPOSITION: Total 90% of water content is 
present in mushroom. After removal of water 
mushroom powder consist of protein (10-40%), fiber 
(3-32%), carbohydrate (3-28%) along with less 
amount of vitamins and minerals22 Apart from  
that G. lucidum has many distinctive bioactive 
molecules23. 
Amino Acid Analysis of G. lucidum Extract: The 
crude extract of G. lucidum consists of 15.6% proteins 
and various amino acid abundance is listed in Table 2 
in decreasing order of relative abundance. Glutamic 
acid and methionine occur with maximum and 
minimum relative abundance respectively24. 
Biologically Active Compounds in G. lucidum: A 
numerous number of biologically active compounds 
have been reported in G. lucidum (Table 3). These 
compounds are associated with a variety of functions 
and effects. These include inhibition of sarcoma, 
neutrophils, apoptosis and phagocytosis. Many tumor 
and growth inhibitors, stimulation of interleukins and 
immune response, β-lymphocytes as antioxidants. The 
most important bioactive of G. lucidum include the 
triterpenoids (Ganoderic acids, Ganoderic Alcohols, 
Lucidenic Acids) and the polysaccharides25. The 
chemical structures of some bioactive compound are 
given in Fig. 2. 
 
MAJOR THERAPEUTIC APPLICATIONS OF 
G. lucidum 
Various number of clinical impact has been 
reported such as immunomodulating, anti-
atherosclerotic, anti-inflammatory, chemo-preventive, 
analgesic, anti-tumor, sleep-promoting, anti-bacterial, 
anti-viral (including anti-HIV), hypo-lipidemic, radio-
protective, anti-fibrotic, hepato-protective, anti-
diabetic, antioxidative and anti-aging, free radical-
scavenging, hypoglycemic and antiulcer effects in G. 
lucidum20,26-28. It is also identified as alternative 
medicine in the therapy of leukemia, hepatitis, 
carcinoma and diabetes29-32. Role of G. lucidum in  
a different therapeutic applications (Fig. 3) in  
detailed below. 
Anti-Human Immunodeficiency Virus (HIV) 
effect: AIDS induced through HIV infection has 
become a significant social and medical issue with in 
vitro research of various G. lucidum triterpenoids 
have an efficient inhibitory activity toward HIV33. 
Likewise, Lucidenic acid and Lucidenic lactones that 
suppress the fuction of DNA polymerase in calf and 
rat, these two compound extracted from G. lucidum, 
along with inhibits HIV-1 RT34. McKenna et al. 
isolated Ganoderiol F and ganodermanontriol from its 
fruiting part are inhibit growth of HIV-1 with an IC100 
of 7.8 µg/mL26. Additionally, some compounds like 
that, ganodermanondiol, ganolucidic acid A, 
ganoderic acid, ganodermanontriol and lucidumol B 
showed significantly anti-HIV-1 protease activity. It 
states that there is a structural activity connection for 
triterpenoids demonstrating against protease activity 
 
  
Fig.1 — Cultivation of G. lucidum 
 
 
Table 2 — Relative abundance of amino acid in G. lucidum 
S.No. Amino Acid Relative abundance 
1 Glutamic acid 120 
2 Aspartic acid 117 
3 Glycine 108 
4 Alanine 100 
5 Threonine 66 
6 Valine 61 
7 Proline 60 
8 Leucine 55 
9 Serine 54 
10 Isoleucine 36 
11 Phenylalanine 28 
12 Arginine 22 
13 Lysine 21 
14 Tyrosine 16 
15 Histidine 12 
16 Methionine 06 
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of HIV with specially C3, C24 or C25 atoms of 
triterpenoids35. 
Immunological effects: G. lucidum comprises 
protein (LZ-8), polysaccharides (D-glucan) and 
 
Table 3 — List of Biological active compound present in G. lucidum 
S.No. Compound Detection method Function/ Nature References 
1. Polysaccharides    
i (1→3)-β-D-glucans Chromatography Inhibition of growth of sarcoma S 180 tumor in mice  80 
ii PS-G, protein-bound 
polysaccharides 
(95% polysaccharides and 5% 
peptides) 
Biochemical Activation of immune response, stimulation of the IL-1β, 
IL-6, TNF-α, 
and IFN-γ production by macrophages and  
T lymphocytes  
40 
iii   Inhibition of neutrophil apoptosis  81 
iv   Induction of neutrophil phagocytosis  82 
v   Induction of GST  83 
vi G009, aminopolysaccharides  Chromatography Antioxidant 84 
vii Glycoproteins (with fructose)  Chromatography Stimulation of IL-1, IL-2 and IFN-γ expression in spleen 
cells 
85 
viii GLIS, proteoglycans  Chromatography Activation of B-lymphocytes 86 
ix Cerebrosides  Chromatography Inhibition of DNA-polymerase 87 
2. Triterpenes    
i Ganoderic acid (U, V, W, X, Y)  Chromatography Cytotoxic for hepatoma cells 88 
ii Ganoderic acid (A, C)  Chromatography Inhibition of farnesyl protein transferase 43 
iii Lucidimol (A, B), 
ganodermanondiol, 
Ganoderiol F, ganodermanontriol  
Chromatography Cytotoxic for sarcoma and lung carcinoma cells 35,89,90 
iv Ganoderic acid F  Chromatography Inhibition of angiogenesis 91 
 Ganodermic acid G Chromatography Direct lethal effect on Meth-A cancer cell 89 
 Ganoderic acid B Chromatography oxidization and hydroxylation were the common  
metabolic pathways for GAB in rats 
92 
 Ganoderic acid T  Chromatography inhibit tumour invasion by inhibiting Matrix 
Metalloproteinase (MMP)-9 expression 
17 
 
 Ganoderic acid D Chromatography contribute to the apoptosis observed in HeLa cell 93 
 Ganoderic acid 24 Chromatography fungal apoptosis and enhancing 
Secondary metabolite production in fungi. 
94 
v Phenols  Biochemical Antioxidant 95 
vi Lipids  
 
Chromatography Growth inhibition of hepatoma, sarcoma S-180 and 
reticulocyte sarcoma L-II in vivo 
96 
 
  Fig.2 — Chemical structure of different terpenoids extracted from G. lucidum 
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triterpenoids, which showed the significant 
immunomodulating activity. The significant 
immunomodulating impacts of such active 
components include mitogenicity and activation of 
immune effectors cells i.e., T-cells, macrophages and 
NK cells, resulting in cytokine manufacturing, 
including IL, tumor necrosis factor (TNF-) and 
interferons. Different types of extracts of G. lucidum 
apotent activator of T cells, which produces a various 
number of cytokines specially IL-236. Crude water 
extract of G. lucidum triggered the expression of 
different kind of cytokines such as IL-10, TNF-, IL-1, 
IL-6 and IL-2 in human PBMC (mainly T cells)37. A 
polysaccharide fraction (GL-B) facilitated 
development of IL-2 and significantly increased the 
effect of cytotoxicity in cytotoxic T lymphocytes38. In 
another study, a polysaccharide extracted using water 
increased the cytotoxicity of splenic NK cells in 
tumor bearing mice39. In our body, macrophages are 
the primary line of protection and its processing  
starts using the substance by G. lucidum resulting  
in cytokine-free, nitric oxide (NO) and other 
facilitators40. 
Effects on Complement System: Both classical 
and alternative pathways of complement system are 
activated by alkaline extraction of different 
compounds from mycelium of G. lucidum41. Fraction 
of it also stimulates mice reticuloendothelial system in 
carbon consent as well as improved hemolytic sign 
for development of spleen cells. The extract of alkali 
contains mainly 49% protein along with 10% 
carbohydrate. Another medical study reported that old 
patients with insomnia palpitation showed that G. 
lucidum essentially improved their C3 concentration 
for 4-6 weeks42. 
Antitumor Activity: Among the various 
compounds, polysaccharides (D-glucans, 
heteropolysaccharides and glycoproteins) and extracts 
of G. lucidum performed function against sarcoma 
180 in mice29, While, in case of triterpenoids, such as, 
ganoderic acids T-Z significantly showed activity in 
hepatoma cells in vitro43. A lanostanoid, 3-hydroxyl-
26-oxo-5-lanosta-8,24-dien-11-one and a steroid, 
ergosta-7,22-diene-3,3,9–triol extracted from G. 
lucidum fruiting bodies showed potential suppressive 
effects on KB cells and human PLC/PRF/5 in vitro44. 
Among cases polysaccharide induces the immune 
function through foremost mechanism of antitumor 
action by G. lucidum. Between various 
polysaccharide only one of the significant substance 
(D-glucans) showed antitumor effects45. 
Anti-Diabetic Effects (Diabetes Mellitus): The 
aqueous extract of G. lucidum have a potential of 
hypoglycemic and hypolipidemic action for 
normalization of glucose concentrations in blood 
during alloxan-induced diabetes Wistar rats. This 
extract slows down the enhanced blood glucose level 
concentration within rats for glucose testing. 
Concerning adrenaline (iv) or oral glucose in rats, 
mushroom inhibited enhanced blood glucose without 
increasing blood insulin concentrations46. Glycans 
(ganoderans B, D) also showed important 
hypoglycemic action in mice, in which Ganoderan B 
was revealed to boost and reduce plasma insulin and 
hepatic glycogen quantity using a mouse model and 
alters the activity of glucose metabolizing enzymes in 
liver47. Clinical research was conducted to evaluate 
the anti-diabetic effectiveness of polysaccharide 
fractions obtained with G. lucidum (Ganopoly) by a 
patented method in 71 patients with reported Type II 
 
  
Fig.3 — Major therapeutic application of G. lucidum 
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diabetes mellitus48. Triterpenoids of G. lucidum were 
showed inhibitory activity on aldose reductase and  
α-glucosidase that can repress postprandial 
hyperglycemia49. 
Hepatoprotective Effect: Ganoderic acids R, S 
and ganosporeric acid A manifest the in vitro 
antihepatotoxic activity against hepatocytes cells in 
rat50. In another study the ethanolic extract of 
triterpenoids of G. lucidum can protect mice towards 
the disease of hepatic necrosis initiated by chloroform 
and d-galactosamine24. 
Anti-Inflammatory Property: The water extract 
of G. Lucidum was found to have important activity 
toward carrageenan in caused paw oedema when it 
applied intravenously to rats51.Moreover, 100 distinct 
strongly oxygenated lanostanoid triterpenes were 
present in Reishi mushroom. Ganoderic acids A-Z are 
significant triterpenes. In addition the extraction of 
ganoderic acid C using non-polar solvent of G. 
lucidum. It has contained most anti-inflammatory 
activity using histamine release from mast cells 
detected through in vitro tests. Another group of 
scientists later discovered the rich content of 
ganoderic acids in ethyl acetate to show countable 
anti-inflammatory activity in conventional animal 
models, including the croton oil-induced mouse ear 
inflammation test52. 
Anti-Allergic Property: The G. lucidum fruiting 
portion was generally used as an anti-inflammatory 
agent to heal allergy or asthma. These two (allergy 
and asthma) are two significant examples of 
histamine-mediated allergic reactions53. The present 
strategy to anti-allergic studies is specific to a target, 
further another study; it is a potential cause in patients 
with a histamine-mediated allergic reaction to repair 
the balance among TH1 and TH2 cytokines52. 
Anti-Androgenic Activity: The Androgen-
mediated diseases i.e. prostate cancer, hirsutism, acne 
androgenic alopecia and Benign Prostatic Hyperplasia 
(BPH) are considered as a massive issues53. The 
fundamental hormone behind prostatic androgen is 
dihydrotestosterone (DHT), that is produced from its 
substrate testosterone by the steroid enzyme 5-
reductase (Type 1 & 2 isozymes)54. Further in another 
case, its ethanolic extract indicates inhibitory activity 
on 5-reductase (isozymes) and down-regulation of 
androgen receptor (AR) signaling via extracted 
ganoderol B from the fruiting part of it and gives the 
mechanism to ganoderol B binding with AR can 
reduce cell growth of androgen-induced LNcaP and 
ventral prostrate regrowth due to testosterone in rat55. 
TLC analysis recommended that G. lucidum 
triterpenoids may be a helpful substance in cure of 
BPH. Another research showed that extract of G. 
lucidum has the more significant 5-reductase 
inhibitory activity of BPH56,57. 
Anti-Angiogenic Activity: The Angiogenesis is a 
physiological method related to the development of 
new blood cells from previous blood cells. It is a 
common method in growth and development as well 
as tissue repair. This effect can significant factor to 
the treatment for cancer victims. The extract of G. 
lucidum performed the this activity and reduce the 
production of inducible free radical component such 
as nitric oxide (NO). In addition, 70% eththanolic 
extract of fruiting bodies (G. lucidum) showed these 
type of activity. Hence, It can be used as an admirable 
agent for controlling angiogenesis58. 
Anti-Herpetic Activity: Herpes simplex virus 
(HSV) caused the viral disease i.e. herpes simplex. It 
is of two types such as HSV-1 and HSV-2. G. 
lucidum has been showing the significant inhibitor of 
both HSV-1 and HSV-2. Acidic protein bound 
polysaccharide (APBP) extracted from the G. 
lucidum. which showed the anti-herpetic actions59. 
APBP was efficient toward viral activity in conjuction 
with HSV-1 and HSV-2 in vitro cells at an efficient 
quantity of 50% of 300 and 440 µg/mL. Protein 
bound polysaccharide like that GLhw, GLhw-01, 
GLhw-02 and GLhw-3 isolated from the G. lucidum 
and these polysaccharides showed the anti-hepatic 
activities60. Between APBP and GLhw-02, GLhw-02 
contains the future prospective development of new 
antihepatic agent. Therefore, G. lucidum acts as a 
powerful inhibitor of both HSV-1 and HSV-2. 
Anti-Oxidant Property: As we know that fungus 
has very less capacity for anti-oxidant activity, in 
contrast G. lucidum has been significant property of 
scavenging of free radicals as we as it contains lipid 
by oxidation reduction property61. The methanol and 
chloroform extracts of G. lucidum showed the 
antioxidant properties. Its chloroform extract does not 
show superoxide scavenging activity and it is of 
forthcoming understanding as major sources of 
ordinary antioxidants in the different food and 
cosmetic company62. 
Anti-Microbial Activity: So many research have 
shown that G. lucidum contains antimicrobial 
components that inhibit bacteria, viruses and fungi32,63. 
The aqueous extract of G. lucidum with combination of 
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four antibiotics (chloramphenicol, cefazolin, ampicillin 
and oxytetracycline) show the effects in main cases: 
Synergism in two situations while combined with 
cefazolin toward Bacillus subtilis, Klebsiella oxytoca 
and antagonism in two context, but in another research 
it was observed that some antifungal compounds were 
extracted from G. lucidum such as Ganoderma 
(antifungal protein)63,64. Ganoderma has inhibited the 
growth of mycelial in Botrytis cinerea, Physalospora 
piricola as well as Fusarium oxysporum. Five 
compounds extracted from G. lucidum carpophores in 
case of anti-viral activity such as GLhw, GLMe-1,-2,-
4, and -7 noticeably inhibited the cytopathological 
impact of Vesicular Stomatitis Virus (VSV) and 
Herpes Simplex Virus (HSV)65. Polysaccharides of G. 
lucidum act as prebiotics composition has been also 
reported to decrease mice obesity by modulating gut 
microbiota structure and potentially contribute to the 
good health66,67. 
Estrogenic Activity: Osteoporosis, a bone 
deformity that results in an increased likelihood of 
fracture, is significantly affected by hormonal 
influences such as absence of estrogen (e.g. due to 
menopause), improves bone resorption and decreases 
the deposition of fresh bone that generally occurs in 
weight-bearing bones and has shown the preventive 
impact of osteoporosis by G. lucidum. According to 
the Song et al., the ethanolic extract of G. lucidum had 
significant impact on breast cancer in human being 
through proliferation of MCF-7 cells. This 
proliferation activity was inhibited by the addition of 
anti-estrogenic compound57. G. lucidum ethanol 
extract suppressed ovariectomy induced bone defeat 
and reduced the amount of osteocalcin in blood 
serum, comparable to 17-estradiol intervention. The 
research has given proof that ethanolic extract of G. 
lucidum has significant property against bone 
resorption that was induced by estrogen deficiency 
devoid of a significant impact on the uterus. There 
results indicated that G. lucidum may be a useful 
component for osteoporosis treatment. 
Anti-Mutagenic Effect: Methanolic extract of G. 
lucidum showed the anti-mutagenic effect on hepatic 
infection caused by benzo[a]pyrene68 and also 
reported significant inhibition (p<0.001). Dose-reliant 
His+ revertants were caused by invitro sodium  
azide (NaN3), N-methyl-N-nitro-N-nitrosoguanidine 
(MNNG) & 4-nitro-phenylenediamine (NPD) and 
benzo[a]pyrene (B[a]P), as well as B[a]P function on 
hepatic enzyme i.e., serum glutamate oxaloacetate 
transaminase (GOT), glutamate pyruvate 
transaminase (GPT) and alkaline phosphatase (ALP). 
The methanolic extract as well prevented the amplify 
the SGOT, SGPT and ALP activities resulting to 
B[a]P challenge and enhanced the levels of different 
reduced glutathione (GSH) and activities of 
glutathione peroxidase (GPx), glutathione-S-
transferase (GST), superoxide dismutase (SOD) and 
catalase (CAT) enzyme. The finding indicated that G. 
lucidum extracts revived antioxidant protection and 
avoided hepatic harm resulting in B[a]P challenge.  
Anti-Ulcerogenic Effect: There are different types 
of ulcers detected such as oral, peptic, corneal, venous, 
genital. G. lucidum seems to be one of the curative 
ulcers. Polysaccharides of G. lucidum had a specific 
mucosal effect on the rat infected with indomethacin. 
The potential pathways associated were explored by 
determining the activity of the gastric mucosal mRNA 
and protein concentrations of TNF and ornithine 
decarboxylase (ODC). The study also examined the 
effects of GLPS on cell proliferation, ODC and c-Myc 
protein expression and mucus synthesis in the gastric 
cell culture (RGM-1). In addition, GLPS improved 
expression of c-Myc protein at a fixed concentration. 
These finding indicates the GLPS produced a mucosal 
healing effect in the rat, potentially primarlily owing to 
the removal of TNF, c-MYc and ODC gene induction. 
It may also be apparent that G. lucidum has an anti-
ulcerogenic impact25. 
Anti-Proliferative Activity: G. lucidum causes 
apoptosis in leukemia, lymphoma along with 
numerous myeloma cells63. Using a number of human 
cancer lines, six hematologic cell lines together with 
leukemia, lymphoma and numerous myeloma cells 
were found to be most sensitive when G. lucidum 
extract was evaluated for its anti-proliferative activity. 
These finding show that G. lucidum extract might be a 
narrative adjuvant treatment for the cure for 
hematological malignancies. Ganoderic acid T (GA-
T), a lanostane triterpenoid purified from the 
methanol extract of G. lucidum mycelia, has been 
found to be cytotoxicity on various cell lines of 
human carcinoma69.  
Cardiovascular: Introduction of 5% of the 
powdered mycelium of G. lucidum in diet of a rat for 
4 weeks significantly decreased the total plasma 
cholesterol (by 18.6%) compared to controls. In the 
reishi-fed group, complete liver triglyceride and 
complete liver cholesterol concentrations were also 
considerably smaller70,71.  
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Anti-inflammatory: G. lucidum extracts are an 
efficient anti-inflammatory agent. The fruiting 
body’s water extract was effective orally against 
both carrageenan-induced infection and croton oil-
induced infection. The extract of ethyl acetate was 
an anti-inflammatory agent both orally and 
topically. The active compound has been separated 
and recognized. This compound is similar to 
hydrocortisone in anti-inflammatory activity. This 
compound is similar to hydrocortisone in anti-
inflammatory activity. It has not shown any typical 
side effects of steroids i.e. thymic involution, that 
does not appear to cause gastropathy, which is a 
significant side effect of non-steroidal anti-
inflammatory drugs like that aspirin72. 
 
Industrial application of G. lucidum 
The worldwide production of G. lucidum was 
5000-6000 MT approximately, out of this more than 
fifty percentage production from only China73,74. As 
we know that, many of the products are available in 
the market, in which some are discussed here. Such 
as, CV Skinlabs Body Repair Lotion, USA and Skin 
relief face mask is a useful product for the wound 
healing and anti-inflammatory properties75. In 
addition, for the current of skin anti-aging and anti-
wrinkle different product are present in the market 
like that, moisturizing body cream76. Guangzhou 
Bocaly Bio-tec and Guangzhou Ocean Cosmetic 
Beauty (www.vegamebeljepara.com), MAVEX 
(www.dazzlingroup.com) and Pureology Nano Words 
Shineluxe77. 
 
Conclusion 
The G. lucidum is a traditionally medicinal macro-
fungus that has been used since many thousands of 
years for its different biological activity. Most 
important components of G. lucidum are triterpenoids 
and polysaccharides. Triterpenoids have been exposed 
to reduce the toxicity of the liver, decrease the 
development of cancerous tumors, lower cholesterol 
and ameliorate complications linked to diabetes 
mellitus. G. lucidum polysaccharides also have 
cancer-fighting characteristics mainly owing to the 
modulation of the immune system and the cellular 
defense against free radicals. G. lucidum might have 
beneficial in the cure of anti-diabetic diabetes mellitus 
II. The fungus eliminates the toxicity caused by other 
therapies such as cancer radiotherapy. The elucidation 
of the G. lucidum genome allows this organism for 
further studying of secondary metabolites. 
Future scope 
Since last 40 years, the genus G. lucidum has been 
broadly researched in order to find new therapeutic 
metabolites. This review article has summarized to its 
various bioactive compounds with their therapeutic 
value, the majority of them being either lanosterol 
derivatives or polysaccharides. Some bioactive 
compounds with cytotoxicity against various cancer 
cell lines, anti-inflammatory, antiviral and 
hepatoprotective activity, along with the 
polysaccharides boost the immune system and exert 
free-radical scavenging activity. However, since this 
genus is one of the largest member belonging to the 
family ganodermataceae; there is still an abundance of 
room for further research. Mushrooms can also be 
utilized as bioreactors in the industry for the 
combination of proteins and pharmaceutical 
compounds78. Cultivation of new mushroom cultivars 
with narrative and enhanced characteristics will 
provide to a company with alternatives to solve food 
issues79and increase the efficiency of manufacturing.  
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